Zoetis' Strong Growth in Q1 2024 Earnings Despite Global Uncertainty

Friday, 3 May 2024, 13:00

Zoetis reports outstanding first quarter results with a 12% operational revenue growth, driven by strong performance in companion animal portfolio. The launch of osteoarthritis pain franchise, Trio, showed significant growth with 61% increase. In the U.S., the product saw a 61% growth with no notable channel dynamics. The quarterly progression for Librela in the U.S. is expected to follow the trend of initial uptake more in severe cases, progressing to moderate cases over time.

https://store.livarava.com/b9b0105b-094f-11ef-a6c1-63e1980711b2.jpg — Zoetis' Strong Growth in Q1 2024 Earnings Despite Global Uncertainty

Zoetis Earnings Report Overview

Q1 2024 Highlights:

12% operational revenue growth
Strong demand for Trio, showing 61% growth

Growth Forecast:

Expected steady growth in Trio sales quarterly
Anticipated progression of Librela uptake from severe to moderate cases in the U.S.

Zoetis demonstrates resilience and promising growth prospects despite global market uncertainties.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Zoetis Earnings Report Overview

Q1 2024 Highlights:

Growth Forecast:

Related posts